The analgesic dihydroergotamine (DHE) has perhaps the longest track record of any effective migraine medicine. Seattle-based Impel NeuroPharma (NSDQ:IMPL) aims to reestablish DHE as a cornerstone of acute migraine treatment following the FDA approval of Trudhesa, a DHE nasal spray. Trudhesa uses the company’s Precision Olfactory Delivery (POD) that delivers the drug to the vasculature…
Impel NeuroPharma wins FDA approval for migraine nasal spray
Impel NeuroPharma (NSDQ:IMPL), a biopharma founded in 2008, has won FDA approval for Trudhesa (dihydroergotamine mesylate) nasal spray as an acute migraine therapy. The Seattle-based company intends to launch the drug, formerly known as INP104, in early October 2021. Impel plans to price the drug between $600 and $850 for a package with four doses.…